Natural Polymorphisms in Mycobacterium tuberculosis Conferring Resistance to Delamanid in Drug-Naive Patients-Reference-Cited by-同舟云学术

Natural Polymorphisms in Mycobacterium tuberculosis Conferring Resistance to Delamanid in Drug-Naive Patients

Published:2020-10-20 Issue:11 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Reichmuth Martina L.¹^ORCID,Hömke Rico²³,Zürcher Kathrin¹,Sander Peter²³^ORCID,Avihingsanon Anchalee⁴,Collantes Jimena⁵,Loiseau Chloé⁶⁷,Borrell Sonia⁶⁷,Reinhard Miriam⁶⁷,Wilkinson Robert J.⁸⁹¹⁰,Yotebieng Marcel¹¹¹²,Fenner Lukas¹^ORCID,Böttger Erik C.²³,Gagneux Sebastien⁶⁷,Egger Matthias¹¹³,Keller Peter M.²³¹⁴^ORCID

Affiliation:

1. Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland

2. Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland

3. Swiss National Center for Mycobacteria, Zurich, Switzerland

4. The HIV Netherlands Australia Thailand (HIV-NAT) Research Collaboration, Thai Red Cross AIDS Research Centre and Tuberculosis Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

5. Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru

6. Swiss Tropical and Public Health Institute, Basel, Switzerland

7. University of Basel, Basel, Switzerland

8. Wellcome Centre for Infectious Diseases Research in Africa, University of Cape Town, Cape Town, Republic of South Africa

9. Department of Infectious Diseases, Imperial College, London, United Kingdom

10. The Francis Crick Institute, London, United Kingdom

11. National TB Lab, Kinshasa, Democratic Republic of the Congo

12. Albert Einstein College of Medicine, New York, New York, USA

13. Centre for Infectious Disease Epidemiology and Research, Faculty of Health Sciences, University of Cape Town, Cape Town, Republic of South Africa

14. Institute for Infectious Diseases, University of Bern, Bern, Switzerland

Abstract

Mutations in the genes of the F 420 signaling pathway of Mycobacterium tuberculosis complex, including dnn , fgd1 , fbiA , fbiB , fbiC , and fbiD , can lead to delamanid resistance. We searched for such mutations among 129 M. tuberculosis strains from Asia, South America, and Africa using whole-genome sequencing; 70 (54%) strains had at least one mutation in one of the genes.

Funder

Foundation for the National Institutes of Health

Wellcome Trust

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00513-20

Reference36 articles.

1. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB)